Novack Jeffrey Adam sold $332K of CDNA

Novack Jeffrey Adam (Secretary and General Counsel) sold 4,096 shares of CareDx, Inc. (CDNA) at an average of $81.13 ($80.47–$83.33, $0.33M total) across 3 trades on 2026-11-10 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · Novack Jeffrey Adam
Published Nov 12, 2026, 9:29 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Nov 12, 2026, 9:36 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$CDNA
Bearish
medium confidence
Mentioned
$CDNA
Relevance
3/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$CDNABearishLow
01

Why it matters

The disclosed sale is modest in dollar terms and executed via a pre‑arranged plan, limiting its immediate market impact but still noteworthy for traders monitoring insider activity.

02

Market read

A small insider sell that may cause slight short‑term pressure on CDNA but is unlikely to move the broader market.

03

What to watch

Potential tax planning or diversification motives behind the 10b5‑1 execution.

Relevance 3/10Novelty 3/10Timing: post‑market today

Background

Form 4 filings provide the first public disclosure of insider transactions.

Company-level read

Ticker impact

$CDNABearishMedium confidence
Context

SEC Form 4 disclosed that CareDx secretary and general counsel sold 4,096 shares for $332K via a 10b5-1 plan.

Expected impact

likely slight pressure as the market prices in the insider sell.

Evidence & confidence

The sale size is modest ($332K) and executed under a pre‑arranged plan, limiting immediate impact but could prompt short‑term downside bias.

Market effects

Minimal; only affects CareDx shareholders.

None

None

Counterpoint

The sale may be routine and not indicative of underlying fundamentals.

Key entities

  • CareDx, Inc.

    Biotech firm listed on NASDAQ under ticker CDNA.

  • Novack Jeffrey Adam

    Secretary and General Counsel of CareDx.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$CRWVMed

Futures Rise As CoreWeave Calms Debt Jitters, Sparking AI Rebound; Oil Jumps On Hormuz Mines

US futures rise as CoreWeave (CRWV) boosts its revenue forecast, easing debt concerns. AI sector gains momentum with reports of Anthropic's potential $1.5T IPO and OpenAI's $10B quarterly revenue. Nasdaq futures recover Tuesday's losses, while Treasuries near 5% on 10Y. Oil jumps on Strait of Hormuz tensions. CoreWeave shares up 15% premarket. NVDA +5.1%, TSLA +2%, GOOGL +1.2%.

$CDNALow

Why CareDx Stock Soared Today

CareDx (CDNA) shares rose 22% after Q3 revenue surged 39% YoY to $139M, driven by 65% growth in testing services. Testing volumes increased 51% to 75,900, aided by the Naveris acquisition. EBITDA doubled to $30M. The company raised full-year revenue guidance to $525M and adjusted EBITDA targets to $90M-$100M, citing growing interest in precision medicine diagnostics.

$CDNAHighAI 8/10

CareDx Soars 20% on Big Q3 Beat and Guidance Raise

CareDx's shares rose 20% after Q3 revenue increased 39% to $139M, surpassing expectations. The company raised 2026 revenue guidance to $520M-$530M. Adjusted EBITDA doubled to $30M. Natera, a competitor, reports next week, which may indicate market growth or share shifts.